Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

By Zacks Investment ResearchStock MarketsAug 13, 2017 10:37PM ET
www.investing.com/analysis/gerons-gern-imetelstat-progressing-well-setbacks-concern-200207094
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
By Zacks Investment Research   |  Aug 13, 2017 10:37PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
ACAD
-3.87%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GERN
-6.48%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ENZ
-0.91%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
KDNY
-1.37%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

We issued an updated research report on Menlo Park, CA-based Geron Corporation (NASDAQ:GERN) on Aug 11.

Geron is developing anti-cancer therapies based on telomerase inhibitors. The company currently has one candidate in its pipeline, imetelstat. It is being developed for the treatment of hematologic myeloid malignancies like myelofibrosis (MF) and myelodysplastic syndromes (MDS). Geron has a collaboration with Johnson & Johnson’s (JNJ) subsidiary Janssen for imetelstat.

Geron has no approved product in its portfolio and its top line solely comprises license fees and royalties.

Imetelstat is being evaluated for myelofibrosis (MF) in a phase II IMbark study and for myelodysplastic syndromes (MDS) in a phase II/III IMerge study.

Geron announced in Apr 2017 that Janssen has completed the second internal data review of the two studies. Janssen said that the benefit/risk profile of imetelstat in the treated patients supports continued development in lower risk MDS indication. Owing to the favorable update, both trials are continuing unmodified.

If Janssen decides to proceed to Part 2 of IMerge (a larger, 170 patient, phase III study), patient enrollment is expected to begin in the fourth quarter of this year. Moreover, Geron announced in July that Part 1 of IMerge will be expanded to enroll additional patients in a refined MDS population to confirm the clinical benefit and safety observed from the current result.

Meanwhile, the results from IMbark study suggested that the clinical benefit and a potential overall survival benefit observed supports continuation of the trial without modifications. Janssen is expected to evaluate maturing data from the IMbark study next year, including an assessment of overall survival.

Geron’s shares have underperformed the industry so far this year. Shares of Geron rose 0.5% during the period compared with the industry’s gain of 6.2%.

However, we are concerned about Geron’s dependence on a single pipeline candidate. Geron has faced setbacks as imetelstat was placed under clinical hold in 2014. It also faced unfavorable findings in internal reviews of initial data from IMbark and IMerge studies. Any further setback may have significant negative impact on the company’s stock.

Zacks Rank & Stocks to Consider

Geron carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , Aduro Biotech, Inc. (NASDAQ:ADRO) and Enzo Biochem, Inc. (NYSE:ENZ) . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ACADIA Pharma’s loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. The company came up with a positive earnings surprise in two of the four trailing quarters with an average beat of 3.25%. The stock is up 8.2% so far this year.

Aduro Biotech’s loss per share estimates narrowed from $1.46 to $1.36 for 2017 and $1.54 to $1.26 for 2018 over the last 30 days. The company delivered a positive surprise in two of the four trailing quarters with an average beat of 2.53%.

Enzo Biochem’s loss estimates narrowed from 12 cents to 7 cents for 2017 and 11 cents to 3 cents for 2018 over the last 60 days. The company came up with a positive earnings surprise in the four trailing quarters with an average beat of 55.83%. The stock is up 59.3% so far this year.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>



Geron Corporation (GERN): Free Stock Analysis Report

Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report

Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report

Original post

Zacks Investment Research
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
 

Related Articles

Declan Fallon
Relief Bounce Negated In One Day By Declan Fallon - Sep 30, 2022 2

It was always going to be a tough sell given the speed at which markets pushed down into a retest of June lows last week, but I would have thought a bounce would have lasted longer...

Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email